Acumen Pharmaceuticals (ABOS) Accounts Payables (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Accounts Payables of $1.7 million for Q1 2026, up 198.74% sequentially from $554000.0 in Q4 2025, and up 56.72% YoY from $1.1 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Accounts Payables (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Accounts Payables for 7 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Accounts Payables rose 56.72% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 56.72% YoY) and the FY2025 annual result came in at $554000.0, down 90.19% from the prior year.
- Accounts Payables grew to $1.7 million in Q1 2026 per ABOS's latest filing, from $554000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $5.6 million in Q4 2024 and troughed at $554000.0 in Q4 2025.
- A 5-year average of $2.0 million and a median of $1.7 million in 2026 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 445.55% in 2022, then plunged 90.19% in 2025.
- Over 5 years, Accounts Payables stood at $1.6 million in 2022, then dropped by 15.91% to $1.4 million in 2023, then soared by 309.57% to $5.6 million in 2024, then slumped by 90.19% to $554000.0 in 2025, then jumped by 198.74% to $1.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.7 million, $554000.0, and $682000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 35.57 Mn |
| 10 | Acumen Pharmaceuticals | 229.03 Mn | 229.03 Mn | - | 13.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.38 Mn |
| Mar 31, 2026 | 1.66 Mn |
| Dec 31, 2025 | 554,000.00 |
| Sep 30, 2025 | 682,000.00 |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 5.65 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 762,000.00 |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 382,000.00 |